SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001479290-24-000072
Filing Date
2024-03-21
Accepted
2024-03-21 16:09:03
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A rvnc2023proxystatementdefa.htm DEFA14A 16243
2 revancetherapeuticsinc_vxc.jpg GRAPHIC 610750
3 revancetherapeuticsinc_vxca.jpg GRAPHIC 394326
  Complete submission text file 0001479290-24-000072.txt   1401117
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36297 | Film No.: 24771387
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)